TargetCytochrome P450 3A4(Homo sapiens (Human))
Bristol Myers Squibb Research And Early Development
Curated by ChEMBL
Bristol Myers Squibb Research And Early Development
Curated by ChEMBL
Affinity DataIC50: 2.85E+3nMAssay Description:Inhibition of human CYP3A4 in human pooled liver microsomes in presence of midazolam as substrate preincubated for 30 mins in presence of NADPH follo...More data for this Ligand-Target Pair
TargetCytochrome P450 3A4(Homo sapiens (Human))
Bristol Myers Squibb Research And Early Development
Curated by ChEMBL
Bristol Myers Squibb Research And Early Development
Curated by ChEMBL
Affinity DataIC50: 3.02E+3nMAssay Description:Inhibition of human CYP3A4 in human pooled liver microsomes in presence of testosterone as substrate preincubated for 30 mins in presence of NADPH fo...More data for this Ligand-Target Pair
TargetCytochrome P450 3A4(Homo sapiens (Human))
Bristol Myers Squibb Research And Early Development
Curated by ChEMBL
Bristol Myers Squibb Research And Early Development
Curated by ChEMBL
Affinity DataIC50: 1.64E+4nMAssay Description:Inhibition of human CYP3A4 in human pooled liver microsomes in presence of midazolam as substrate preincubated for 30 mins in presence of NADPH follo...More data for this Ligand-Target Pair
TargetCytochrome P450 3A4(Homo sapiens (Human))
Bristol Myers Squibb Research And Early Development
Curated by ChEMBL
Bristol Myers Squibb Research And Early Development
Curated by ChEMBL
Affinity DataIC50: >3.30E+4nMAssay Description:Inhibition of human CYP3A4 in human pooled liver microsomes in presence of testosterone as substrate preincubated for 30 mins in presence of NADPH fo...More data for this Ligand-Target Pair
TargetCytochrome P450 3A4(Homo sapiens (Human))
Bristol Myers Squibb Research And Early Development
Curated by ChEMBL
Bristol Myers Squibb Research And Early Development
Curated by ChEMBL
Affinity DataIC50: >4.00E+4nMAssay Description:Inhibition of human CYP3A4 in human pooled liver microsomes in presence of midazolam as substrate preincubated for 0 mins in presence of NADPH follow...More data for this Ligand-Target Pair
TargetCytochrome P450 3A4(Homo sapiens (Human))
Bristol Myers Squibb Research And Early Development
Curated by ChEMBL
Bristol Myers Squibb Research And Early Development
Curated by ChEMBL
Affinity DataIC50: >4.00E+4nMAssay Description:Inhibition of human CYP3A4 in human pooled liver microsomes in presence of testosterone as substrate preincubated for 0 mins in presence of NADPH fol...More data for this Ligand-Target Pair
TargetCytochrome P450 3A4(Homo sapiens (Human))
Bristol Myers Squibb Research And Early Development
Curated by ChEMBL
Bristol Myers Squibb Research And Early Development
Curated by ChEMBL
Affinity DataIC50: >4.00E+4nMAssay Description:Inhibition of human CYP3A4 in human pooled liver microsomes in presence of testosterone as substrate preincubated for 0 mins in presence of NADPH fol...More data for this Ligand-Target Pair
TargetCytochrome P450 3A4(Homo sapiens (Human))
Bristol Myers Squibb Research And Early Development
Curated by ChEMBL
Bristol Myers Squibb Research And Early Development
Curated by ChEMBL
Affinity DataIC50: >4.00E+4nMAssay Description:Inhibition of human CYP3A4 in human pooled liver microsomes in presence of midazolam as substrate preincubated for 0 mins in presence of NADPH follow...More data for this Ligand-Target Pair
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 59nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 1.48nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 197nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 197nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 0.950nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 20nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataEC50: 3nMT: 2°CAssay Description:HCV replicon luciferase assays were developed to monitor the inhibitory effects of compounds described in the disclosure on HCV genotypes 1a and 1b v...More data for this Ligand-Target Pair
TargetGenome polyprotein [1028-1200,1251-1711](Hepatitis C virus genotype 1b (strain J4L2S) (HCV))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent